Kura Oncology Inc SEC Filings

Kura Oncology, Inc. (KURA) President and CEO Troy E. Wilson reported the vesting of 182,500 shares of common stock on 11/13/2025. These shares relate to performance-based restricted stock units (PSUs) originally granted on May 31, 2023, which vest upon achievement of specified development milestones and the one-year anniversary of each milestone, subject to continued service. The filing states that the performance criteria for one development milestone were met on November 13, 2025, triggering vesting of one-sixth of the underlying shares at a price of $0 per share. Following this transaction, Wilson beneficially owns 429,353 shares directly, 279,194 shares indirectly through the One Fish Two Fish Revocable Trust, and 300,000 shares indirectly through the Lorax Charitable Remainder Unitrust.

Kura Oncology, Inc. reported an insider equity transaction by its Chief Medical Officer, Mollie Leoni. On 11/13/2025 she acquired 82,500 shares of common stock at a reported price of $0 following the vesting of performance-based restricted stock units tied to a development milestone. On 11/14/2025 she sold 15,485 shares of common stock at $11.1769 per share in a sell-to-cover transaction for taxes related to that vesting. After these transactions, she directly beneficially owned 225,454 shares of Kura Oncology common stock.

Kura Oncology, Inc. (KURA) senior vice president of finance and accounting Thomas Doyle reported equity transactions in a Form 4. On 11/13/2025, he acquired 24,967 shares of common stock at $0, raising his direct holdings to 134,796 shares. On 11/14/2025, he sold 4,539 shares of common stock at $11.1769 per share, leaving 130,257 shares held directly. The sale was described as a sell-to-cover for taxes tied to the vesting of performance-based restricted stock units granted on May 31, 2023, after a specified development milestone was met on November 13, 2025. He also holds 500 shares indirectly through his spouse's 401(k).

Kura Oncology, Inc. (KURA) reported an insider equity transaction by its Chief Operating Officer. On 11/13/2025, the officer acquired 48,900 shares of common stock at $0, reflecting the vesting of performance-based restricted stock units after a development milestone was achieved. On 11/14/2025, 6,902 shares were sold at $11.1769 in a sell-to-cover transaction for taxes tied to this vesting. Following these transactions, the officer directly beneficially owned 105,373 shares of Kura Oncology common stock.

Kura Oncology (KURA) announced that the FDA granted full approval of KOMZIFTI (ziftomenib) for adult patients with relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation who have no satisfactory alternative treatment options. KOMZIFTI is the first and only once-daily, oral menin inhibitor approved for this R/R NPM1‑mutated AML population.

Approval is supported by the pivotal KOMET‑001 trial in 112 patients, showing a complete remission (CR) plus CR with partial hematologic recovery (CRh) rate of 21.4% (95% CI: 14.2, 30.2). Median duration of CR+CRh was 5.0 months (95% CI: 1.9, 8.1), and median time to first response among responders was 2.7 months, with 88% achieving CR or CRh within six months of starting therapy. The label includes a Boxed Warning for differentiation syndrome, and common adverse reactions (≥20%) included liver enzyme elevations, infections, electrolyte changes, hemorrhage, gastrointestinal events, fatigue, edema, and QTc interval prolongation (≤ Grade 3 in 12% of patients; no Grade 4/5 reported). The wholesale acquisition cost for a one‑month supply is $48,500. Kura leads U.S. development, regulatory and commercial strategy and manufacturing under its collaboration with Kyowa Kirin; Kyowa Kirin leads outside the United States.

Kura Oncology (KURA) filed a Form S-8 to register 750,000 additional shares of common stock issuable under its 2023 Inducement Option Plan, as amended. The increase to the plan’s share reserve was approved by the Board of Directors pursuant to Nasdaq Listing Rule 5635(c)(4).

The filing incorporates prior S-8 registrations for the same plan and adds capacity for future inducement equity awards to eligible new employees.

Kura Oncology (KURA) reported Q3 2025 results with collaboration revenue of $20.8 million, driven by its Kyowa Kirin partnership, and a net loss of $74.1 million ($0.85 per share). Operating expenses rose to $100.7 million on higher R&D ($67.9 million) and G&A ($32.8 million).

Liquidity remained strong with $549.7 million in cash, cash equivalents and short-term investments as of September 30, 2025. Contract liabilities tied to deferred collaboration revenue totaled $317.6 million, reflecting services to be delivered; receivables from collaborators were $35.9 million. Shares outstanding were 87.0 million as of October 31, 2025.

The company’s NDA for ziftomenib in relapsed/refractory NPM1-mutated AML was accepted with Priority Review and a PDUFA target action date of November 30, 2025. Kura also amended its term loan on October 25, 2025 to extend interest-only payments, with a further extension possible upon an approval milestone.

Kura Oncology (KURA) furnished an 8-K announcing it issued a press release with financial results for the third quarter ended September 30, 2025, along with a corporate update.

The information under Item 2.02 and Exhibit 99.1 is being furnished, not deemed “filed” under Section 18 of the Exchange Act, and will not be incorporated by reference into Securities Act registrations unless specifically identified.

Kura Oncology announced receipt of a $30 million milestone payment from Kyowa Kirin. The payment was triggered by dosing the first patient in KOMET-017, a pair of Phase 3 registrational trials evaluating ziftomenib, a once-daily, investigational oral menin inhibitor.

KOMET-017 consists of two independent, global, randomized double-blind, placebo-controlled Phase 3 studies. They assess ziftomenib in combination with intensive and non‑intensive chemotherapy in adults with newly diagnosed NPM1‑mutated or KMT2A‑rearranged acute myeloid leukemia. The payment provides non-dilutive funding aligned with the advancement of ziftomenib into late‑stage testing.